Achilles Therapeutics ( (ACHL) ) has shared an announcement.
On March 20, 2025, Achilles Therapeutics held a General Meeting where shareholders approved the commencement of a members’ voluntary liquidation. The Board declared solvency and appointed joint liquidators to oversee the winding up of the company. Key changes in leadership were made, with the resignation of several directors and the appointment of new ones. Additionally, the company delisted its American Depositary Shares from Nasdaq and plans to deregister them, effectively suspending its obligation to file periodic reports. The termination of KPMG LLP as the company’s independent auditor was also approved.
More about Achilles Therapeutics
Achilles Therapeutics is a company operating in the biotechnology industry, focusing on developing personalized T cell therapies for the treatment of cancer. The company’s market focus is on leveraging its proprietary platform to target clonal neoantigens in tumors.
YTD Price Performance: 28.95%
Average Trading Volume: 1,293,390
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $61.24M
Find detailed analytics on ACHL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com